TuHURA Biosciences (NASDAQ:HURA) Given Buy Rating at HC Wainwright

TuHURA Biosciences (NASDAQ:HURA)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $10.00 target price on the stock.

A number of other brokerages have also commented on HURA. Maxim Group reduced their target price on shares of TuHURA Biosciences from $15.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 14th. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Thursday, January 22nd. Finally, Wall Street Zen lowered TuHURA Biosciences from a “hold” rating to a “sell” rating in a research report on Sunday, December 14th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, TuHURA Biosciences currently has an average rating of “Moderate Buy” and an average target price of $9.00.

TuHURA Biosciences Stock Down 3.0%

Shares of TuHURA Biosciences stock opened at $0.52 on Tuesday. The stock’s fifty day moving average is $1.01 and its two-hundred day moving average is $1.99. TuHURA Biosciences has a 52 week low of $0.50 and a 52 week high of $5.03. The company has a market capitalization of $26.60 million, a PE ratio of -1.04 and a beta of 0.12.

TuHURA Biosciences (NASDAQ:HURA) last issued its earnings results on Friday, November 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01.

Institutional Investors Weigh In On TuHURA Biosciences

A number of hedge funds have recently made changes to their positions in HURA. Virtu Financial LLC purchased a new position in shares of TuHURA Biosciences in the third quarter worth $26,000. JPMorgan Chase & Co. acquired a new position in shares of TuHURA Biosciences in the 2nd quarter valued at $27,000. Intech Investment Management LLC acquired a new position in shares of TuHURA Biosciences in the 2nd quarter valued at $29,000. Invesco Ltd. purchased a new position in TuHURA Biosciences in the 2nd quarter worth $30,000. Finally, Merck & Co. Inc. acquired a new stake in TuHURA Biosciences during the 2nd quarter worth about $31,000. 0.62% of the stock is currently owned by hedge funds and other institutional investors.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.